Roche has announced that the European Union has granted CE Mark approval for Contivue®, its Port Delivery Platform (previously branded as Susvimo) for the long-term delivery of ranibizumab. The implant provides continuous treatment for neovascular age-related macular degeneration (nAMD), reducing the need for frequent eye injections.
Durable Treatment for nAMD
Contivue offers a refillable eye implant that can provide sustained therapeutic delivery with only up to two refills per year. This significantly reduces treatment burden for patients compared to monthly intravitreal injections, while maintaining effective disease control.
Clinical Data Demonstrates Long-Term Efficacy
Seven-year follow-up data from the LADDER clinical study demonstrated that patients using the Port Delivery Platform achieved strong visual outcomes and maintained stable retinal anatomy. These results highlight Contivue’s potential to provide durable treatment options in ophthalmology.
Expanding Roche’s Ophthalmology Portfolio
The CE Mark approval of Contivue reinforces Roche’s leadership in ophthalmology and builds on its broader portfolio, which includes therapies such as Vabysmo®. By advancing sustained drug delivery technologies, Roche aims to improve patient outcomes and reduce healthcare system pressures linked to frequent clinic visits.
